{
  "patent_number": "US 20190160160",
  "country": "US",
  "title": "Making Drug Proteins Last Longer and Target Diseases Better",
  "original_title": "Methods to Treat Diseases with Protein, Peptide and Antigen Modification",
  "summary": "This patent describes ways to make protein and peptide drugs stay in the body longer and target specific diseases like autoimmune conditions or cancer more precisely by linking them together or combining them with other molecules.",
  "what_it_does": "This patent describes two main methods to improve drug treatments. First, it details how to extend the active life of peptide drugs in the body (their \"half-life\"). This is done by connecting at least three individual peptide units, called monomers, in a linear chain using a special \"self-immolative linker\" (Claim 1). This creates a larger molecule, an \"oligomer,\" with a total molecular weight greater than 60,000 (Claim 1). The linker is designed to break apart inside the body, releasing the active peptides when needed. For example, this method could be applied to peptides like Exenatide (Claim 3) or CNP peptide (Claim 4). Second, the patent describes creating specialized combinations, or \"conjugates,\" to treat autoimmune diseases, specifically systemic lupus erythematosus (Claim 6). These conjugates combine an \"auto antigen\" (a substance that causes the immune system to attack the body's own tissues, such as B cell antigen or DNA, as in Claims 7-8) with a \"second antigen\" that the body already has natural antibodies against (like alpha-gal or L-rhamnose, as in Claim 9). The goal is to redirect the body's immune response to treat the disease more effectively.",
  "what_it_does_not_cover": [
    "Does not cover extending peptide half-life by connecting fewer than three peptide units.",
    "Does not cover peptide oligomers with a total molecular weight of 60,000 or less.",
    "Does not cover linkers that are not \"self-immolative\" or are not cleavable inside a living organism.",
    "Does not cover conjugates for autoimmune diseases other than systemic lupus erythematosus, unless additional claims specify.",
    "Does not cover conjugates where the second antigen is not something the body already has natural antibodies against."
  ],
  "filed": "2019-02-11",
  "granted": null,
  "expires": "2039-02-11",
  "status": "active",
  "holder": "Individual",
  "holder_url": "https://patentbrief.org/company/individual",
  "inventors": [
    {
      "name": "Tianxin Wang",
      "url": "https://patentbrief.org/inventor/tianxin-wang"
    }
  ],
  "times_cited": 0,
  "tags": [
    "pharmaceutical",
    "biotech",
    "materials"
  ],
  "abstract": "This disclosure provides methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life. This disclosure also provides methods to construct activatable enzyme, which becomes active when they reach the treatment target, therefore provide higher specificity for treatment.",
  "url": "https://patentbrief.org/patent/us/20190160160/methods-to-treat-diseases-with-protein-peptide-and-antigen-modification",
  "markdown_url": "https://patentbrief.org/patent/us/20190160160/methods-to-treat-diseases-with-protein-peptide-and-antigen-modification/md",
  "google_patents_url": "https://patents.google.com/patent/US20190160160",
  "relatedPatents": [
    {
      "patentNumber": "5455030",
      "countryCode": "US",
      "title": "How to Build Smaller, Synthetic Antibody-Like Molecules for Medicine",
      "url": "https://patentbrief.org/patent/us/5455030/immunotheraphy-using-single-chain-polypeptide-binding-molecules"
    },
    {
      "patentNumber": "10314897",
      "countryCode": "US",
      "title": "How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer",
      "url": "https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca"
    },
    {
      "patentNumber": "10106579",
      "countryCode": "US",
      "title": "How Synthetic Peptides Block Immune System Overreaction",
      "url": "https://patentbrief.org/patent/us/10106579/orkambi-lumacaftor-ivacaftor"
    },
    {
      "patentNumber": "9884123",
      "countryCode": "US",
      "title": "Targeted Platinum Drugs for Cancer Treatment",
      "url": "https://patentbrief.org/patent/us/9884123/ligand-targeted-molecules-and-methods-thereof"
    },
    {
      "patentNumber": "6458360",
      "countryCode": "US",
      "title": "How to Create Lab-Made Proteins That Stop Immune System Overreaction",
      "url": "https://patentbrief.org/patent/us/6458360/hpv-vaccine-gardasil"
    }
  ]
}